Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages
Authors:
Open Access
- 16 January 2020
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 12 (2) , 1114-1127
Abstract
Reactive oxygen species (ROS) modulator 1 (Romo1) is a mitochondrial membrane protein that is essential for the regulation of mitochondrial ROS production and redox sensing. Although the physiological functions of Romo1 have been studied for the past few years, the role of Romo1 in cancer remained unclear. In this study, we found that the high expression of Romo1 is associated with the poor prognosis of glioblastoma patients. Further study revealed that Romo1 is highly expressed in macrophages, indicating that the overexpression of Romo1 may participate in the function of macrophages and contribute to the progression of glioblastoma. Through the glioblastoma mouse model, we found that the overexpression of Romo1 in bone marrow cells significantly inhibited the immune response within tumor microenvironment, and that the overexpression of Romo1 resulted in the M2 polarization of bone marrow derived macrophages (BMDMs) through mTORC1 signaling pathway. In addition, the inhibition of Romo1 combining with anti-PD-1 immunotherapy significantly improved the survival outcome of glioblastoma in mouse model. Collectively, our study highlights the important role of Romo1 in immune response especially the function of macrophages, and implicates it as a potential target of immunotherapy for glioblastoma.Keywords
This publication has 26 references indexed in Scilit:
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastomaNature Medicine, 2019
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCNew England Journal of Medicine, 2018
- Current state of immunotherapy for glioblastomaNature Reviews Clinical Oncology, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yetOncotarget, 2017
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)The Lancet, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- A critical role for Romo1-derived ROS in cell proliferationBiochemical and Biophysical Research Communications, 2008